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INTRODUCTION
In recent years remarkable progresses have been
made in ophthalmology. However, there are still
some diseases those are difficult to manage. One of
them is diabetic macular edema. Several treatments
for diabetic macular edema have already been re-
ported. The Early Treatment of Diabetic Retinopa-
thy Study (ETDRS)(1) in the U.S.A. reported the
efficacy of focal photocoagulation for clinically sig-
nificant macular edema (CSME). Recently, the ef-
ficacies of vitrectomy (2, 3) and intravitreal injec-
tion of triamcinolone acetonide (TA)(4 -6) for dif-
fuse diabetic macular edema have also been re-
ported. The sub-Tenon’s capsule injection of TA
(7-9) is easier, and less complicated than its in-
travitreal injection. In addition, the sub-Tenon’s cap-
sule injection of TA with photo-coagulation or
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vitrectomy seems to be more beneficial for diabetic
macular edema. However, the efficacy of such treat-
ments has not been established yet.
Wada, et al. reported that the sub-Tenon’s cap-
sule injection of TA for diffuse diabetic macular
edema tended to be more effective in vitrectomized
eyes than in non-vitrectomized eyes (8). Therefore,
we studied on the efficacy of sub-Tenon’s capsule
injection of TA for refractory diabetic macular edema
after vitrectomy.
MATERIALS AND METHODS
All enrolled patients showed diffuse fluorescein
leakage for diabetic retinopathy involving most of
the macular area as seen by fluorescein angiogra-
phy, and their central macular thickness (CMT) was
measured to be 250 μm by an optical coherence
tomography (OCT) scan. Thirty -nine eyes of 26
patients were selected, and received a sub-Tenon’s
capsule injection of 20 mg TA.
We classified 10 vitrectomized eyes as PPV(+)
group, and 29 non-vitrectomized eyes as PPV(-)
group. The PPV(+)group was followed up for more
than 6 months after vitrectomy when they were
given TA injection. The range of interval between
vitrectomy and the TA injection was from 6 to 48
months (average, 21.1 months). The average follow-
up period of the PPV(+)group was 8.4 months, and
that of the PPV(-)group was 6.2 months after the
initial injection of TA. The mean ages of the PPV
(+) and PPV(-)groups were 61.47.5 (meanSD)
and 63.58.2 years, respectively. Material data are
shown in Table 1.
No patients had received grid-pattern laser pho-
tocoagulation before this treatment. All patients had
received pan-photo coagulation. Informed consents
were obtained from all patients before treatment.
We selected a dosage of 20 mg TA for this treat-
ment as reported by Okada, et al. (10). After topi-
cal anesthesia with 4% lidocaine eyedrops, a small
area of the temporal inferior conjuctival fornix was
incised to show the bare sclera. Through this inci-
sion, TA was injected into the sub-Tenon’s capsule
with a 25 -gauge curved blunt cannula, and the
wound was left unsutured. All patients were in-
structed to instill 0.5% levofloxacin eyedrops five
times a day for 2 weeks.
The efficacy of the sub-Tenon’s capsule injec-
tion of TA was assessed by recording the visual
acuity (VA), CMT, clinical findings using slit lamp
examination and complications such as high in-
traocular pressure (IOP).
We defined more than 20% reduction in CMT
from pre- treatment to treatment time points as an
effective response. In addition, we defined more
than 20% increase in CMT according to the short-
est period between treatment and pre - treatment
time points as recurrence, in effective cases.
These results were analyzed using a one-way or
repeated measure analysis of variance(ANOVA). P
values less than 0.05 were accepted as significant.
RESULTS
Central Macular Thickness (CMT)
The mean CMTs before TA injection, at 1 and
3 months post - treatment were 435  112 μm
(meanSD), 326102 μm, and 30394 μm, re-
spectively. The decrease in the mean CMTs be-
tween the pre - treatment and post - treatment of
1 month or 3 months was statistically significant
(p0.0001, paired t - test). The mean CMTs of the
PPV(+) group at pre - treatment, 1 and 3 months
were 463  142 μm, 287  80 μm, and 264  93
μm, respectively. The mean CMTs of the PPV(-)
group at pre - treatment, 1 and 3 months were 429
 134 μm, 329  101 μm, and 300  97 μm, re-
spectively. The difference in the mean CMTs be-
tween the PPV(+) and PPV(-) group was statisti-
cally significant (p = 0.041, repeated -measure
ANOVA, Fig. 1).
Table 1. Clinical characteristics of the PPV(+)group and the PPV(-)group
Group PPV(+) PPV(-)
Number of the cases 10 eyes 29 eyes
Sex(Male/Female) 8 eyes/2 eyes 24 eyes/5 eyes
Mean age 61.47.5 years 63.58.2 years
Average follow-up period 8.4 months 6.2 months
PPV(+)group, eyes which pars-plana vitrectomy was perfomed
PPV(-)group, eyes which pars-plana vitrectomy was not perfomed
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The efficacy and the rate of recurrence
The numbers of effectively treated cases were 7
eyes(70%) at 1 month and 3 months post-treatment
in the PPV(+)group, and 15 eyes (52%) at 1 month
and 19 eyes (66%) at 3 months in the PPV(-)group.
The numbers of recurrent cases were 1 eye (14%)
in the 7 effective cases of the PPV(+)group, and 3
eyes (16%) in the 19 effectively treated cases of the
PPV(-)group.
The PPV(+) and PPV(-) group did not show any
significant differences in efficacy and rate of recur-
rence.
Visual Acuity and Complications
After the TA injection, the log MAR (minimal
angle of resolution) visual acuity significantly im-
proved from the pre - treatment value at all follow-
up periods. The mean visual acuity improved from
0.860.42 (meanSD) at pre - treatment to 0.76
0.40 at 1 month and 0.700.41 at 3 months post -
treatment. However, the PPV(+) and PPV(-) groups
did not show any significant difference in visual
acuity.
No cases with an IOP elevation exceeding 21
mmHg after TA injection were seen in all 39 eyes.
The progression of cataract, ptosis, and other in-
jection-related complications were not observed,
either.
DISCUSSION
Improving the macular edema that is the most
common cause of visual impairments in diabetic ret-
inopathy is one of the major concerns in ophthal-
mic researches. The efficacy of vitrectomy for dia-
betic macular edema has been assessed, and re-
ported as the prevailing treatment for this condi-
tion. However, the efficacy of vitrectomy has not
been fully established yet, and we have experienced
some cases with refractory macular edema after
vitrectomy. We expected that the sub-Tenon’s cap-
sule injection of TA would be effective for refrac-
tory diabetic macular edema.
In the PPV(+)group, the mean CMTs at 1 month
and 3 months post - treatment were significantly
smaller than those obtained at pre - treatment. This
demonstrates that TA injection could be used as a
short - term treatment even if diabetic macular
edema persists after vitrectomy.
In addition, the mean CMTs after the sub-Tenon’s
capsule injection of TA, in the PPV(+) group, was
significantly smaller than that in the PPV(-) group.
We suppose the following reasons :
1) The retrobulbar TA in the PPV(+) group reaches
to the retina more effectively than that in the
PPV(-) group.
2) We did not randomly choose patients to perform
or not to perform PPV before TA injection. The
PPV(+)group consisted of more severe cases
than the PPV(-)group. In severe cases in which
the sub-Tenon‘s capsule injection of TA worked
effectively, we considered that their macula were
more atrophic and thinner than in the normal
group.
The efficacy and the rate of recurrence at 1 month
and 3 months post - treatment were almost the same.
The efficacy of TA at 1 month post - treatment was as
good as that reported by previous report (8), and
the effects lasted for 3 months. It seems that we
should study longer - term results to investigate the
recurrence which is another major problem of TA
injection. Although the improvement of visual acu-
ity was slight in our study, we got a good impres-
sion on the patient’s subjective improvement be-
cause of the improvement of macular edema.
Our results not only indicate that the sub-Tenon’s
capsule injection of TA is an effective treatment for
refractory diabetic macular edema after vitrectomy,
but also show that vitrectomized eyes were more
effectively responding to TA than non-vitrectomized
eyes.
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